T. Nakanishi

UR-3216: a manageable oral GPIIb/IIIa antagonist.

K. Baba, Y. Aga, T. Nakanishi, 2006, Cardiovascular drug reviews.

Antagonism of PAF-induced death in mice.

P. Ramwell, T. Nakanishi, A. Myers, 1988, Prostaglandins.

Increased plasma levels of damage-associated molecular patterns during systemic anticancer therapy in patients with advanced lung cancer

N. Hamada, Y. Nakanishi, I. Okamoto, 2021, Translational lung cancer research.

UR-3216: a new generation oral platelet GPIIb/IIIa antagonist.

S. Tam, K. Baba, Y. Aga, 2004, Current pharmaceutical design.

Impact of increased plasma levels of calreticulin on prognosis of patients with advanced lung cancer undergoing combination treatment of chemotherapy and immune checkpoint inhibitors.

N. Hamada, I. Okamoto, Tomohiro Ogawa, 2023, Lung cancer.

MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma.

Y. Oda, T. Yoshizumi, I. Okamoto, 2023, Cancer science.

Regulation of PD-L1 expression in non–small cell lung cancer by interleukin-1β

I. Okamoto, Kentaro Tanaka, Y. Yoneshima, 2023, Frontiers in Immunology.